LAVAL, QUEBEC, CANADA, – February 6, 2014 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL"), has entered into a new agreement with a leading vaccines company, for the development of an affinity adsorbent and associated purification process for the production of a novel vaccine product.
Under this new Agreement, PBL will use its ligand design and screening capabilities to identify MimeticTM
affinity ligand(s) with the ability to capture and purify the novel vaccine product. Once suitable ligands have been identified, they will be further developed to provide an affinity resin product and associated process
conditions to be used in commercial vaccine manufacturing by PBL's client.
The Agreement is structured to provide ProMetic with potential initial service revenues of up to $1.6 million over the next twelve months assuming successful completion of ongoing milestones, with work commencing immediately. This agreement is also anticipated to lead to a subsequent long-term agreement for the manufacture and supply of the affinity resin for use in scale-up and commercial production of the vaccine product.
"ProMetic's state-of-the-art affinity technology has demonstrated capability to develop affinity purification solutions for almost any target biomolecule including genetically engineered viral surface proteins which form the basis of a growing number of vaccine products" said Dr. Steve Burton, PBL's Chief Executive Officer. "Vaccines are produced in large quantities and must be highly purified to avoid any unwanted side-effects which are generally considered to be unacceptable in the case of a therapeutic product given to healthy individuals to protect against viral infection" added Dr Burton.
"We are pleased to be adding a new client for which we will have the opportunity to demonstrate the
outstanding performance of our purification technologies", mentioned Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. "We believe our bioseparation solutions to be especially well suited for the purification of products manufactured in large quantities given the superior purification yield and economic advantages they provide", added Mr. Laurin.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (prometic.com) is a long established biopharmaceutical company with
globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic
proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed
assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 26 of ProMetic's Annual Information Form for the year ended December 31, 2012, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other
reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.